1) cholestatic liver diseases
胆汁淤滞性肝病
1.
Methods Twenty-six consecutive cases of cholestatic liver diseases after allogeneic hematopoietic stem cell transplantation were enrolled and randomly divided into 2 groups,the UDCA group(n=12) and the s-adenosyl methionine group(n=14).
目的探讨熊去氧胆酸(ursodeoxycholic acid,UDCA)治疗异基因造血干细胞移植(allogeneic hematopoietic stem cell transplantation,allo-HSCT)术后早期胆汁淤滞性肝病的价值。
3) cholestasis syndrome
胆汁淤积性肝病综合征
1.
Objective To investigate the relationship between human cytomegalovirus(CMV) and infantile cholestasis syndrome and the role that serological assay and molecular diagnostic methods play in diagnosis of CMV infection.
目的探讨人巨细胞病毒感染(CMV)与婴儿胆汁淤积性肝病综合征的关系,以及血清学和分子生物学方法在诊断CMV感染中的作用。
4) cholestasis
[英][,kɔlə'stɑ:sis] [美][,kɑlə'stɑsɪs]
胆汁淤积型肝病
1.
Determination of alkaline phosphatase and its isoenzyme activities in cholestasis in rat;
大鼠胆汁淤积型肝病碱性磷酸酶及其同工酶的测定
5) cholestasis-induced liver fibrosis
胆汁淤积性肝纤维化
1.
Effect of chinese medicine Complex prescriptions of different cure laws on PAI-1 mRNA of cholestasis-induced liver fibrosis rat;
不同治则中药复方对胆汁淤积性肝纤维化大鼠PAI-1影响的研究
2.
Objective To study the regulatory effects of the Chinese medicine complex prescriptions Erzhiwan and Shixiaosan on urokinase type plasminogen activator(uPA)/plasminogen activator inhibitor-1(PAI-1)fibrinolytic system cholestasis-induced liver fibrosis rats.
目的研究不同治则中药复方二至丸与失笑散对胆汁淤积性肝纤维化大鼠uPA/PAI-1纤溶途经的调控作用。
3.
Objective To study the effects of the Chinese herbal compound (Erzhiwan, Shixiaosan and combined formula) on cholestasis-induced liver fibrosis rat’s uPA.
目的观察补益肝肾、活血化瘀方二至丸、失笑散及其合方对胆汁淤积性肝纤维化大鼠肝组织尿激酶型纤溶酶原激活剂(uPA)的影响。
补充资料：胆汁淤滞
胆汁淤滞
由于各种原因引起的胆汁长期在胆道中积聚。长时间致使胆汁不流动，可使胆汁的理化性质发生变化。如水分被过多吸收，发生胆汁过度浓缩，胆色素的浓度增高，胆固醇处于过饱和状态，促进胆石形成，还能使已析出的结石微粒在胆道内沉积，有利于细菌在胆道内生长繁殖，引起感染。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条